文献速递乳腺外科

乳腺癌原发全身治疗后的磁导航手术:对增强腋窝定位的意义

Magnetically guided surgery after primary systemic therapy for breast cancer: implications for enhanced axillary mapping.
PubMed 文献 · Br J Surg · 2024-01-01

这项队列研究纳入113例cN0/1至ycN0的乳腺癌患者,在手术或原发全身治疗前注射超顺磁性氧化铁纳米颗粒,术日加用放射性同位素。超顺磁性氧化铁纳米颗粒检出率为97.4%,放射性同位素为91.2%(P=0.057);两者一致率为97.1%,不受注射时机影响。结论认为原发全身治疗前注射可行,且超顺磁性氧化铁纳米颗粒与放射性同位素表现相当,但检出更多前哨淋巴结及转移性前哨淋巴结。

要点

  • 113例患者中,超顺磁性氧化铁纳米颗粒检出率97.4%,放射性同位素91.2%(P=0.057)。
  • 超顺磁性氧化铁纳米颗粒与放射性同位素一致率97.1%,不受注射时机影响。
  • 靶向腋窝清扫中指标淋巴结磁性检出93.9% vs 放射性66.7%(P=0.007)。

核心结论

  • 原发全身治疗前注射超顺磁性氧化铁纳米颗粒可行,且不影响与放射性同位素的一致率。
  • 超顺磁性氧化铁纳米颗粒与放射性同位素表现相当,但检出更多前哨淋巴结,转移性前哨淋巴结检出率更高。

研究设计与样本

  • 队列研究,纳入cN0/1至ycN0的乳腺癌患者,行前哨淋巴结检出或靶向腋窝清扫。
  • 所有患者在原发全身治疗前或手术前接受超顺磁性氧化铁纳米颗粒,术日接受放射性同位素。
  • 共分析113例患者。

主要发现

  • 超顺磁性氧化铁纳米颗粒注射距手术中位时间3天(范围0-248天)。
  • 超顺磁性氧化铁纳米颗粒检出率97.4%,放射性同位素检出率91.2%(P=0.057)。
  • 与放射性同位素的一致率为97.1%,不受超顺磁性氧化铁纳米颗粒注射时机影响(Kendall's tau 0.027;P=0.746)。
  • 超顺磁性氧化铁纳米颗粒检出的前哨淋巴结中位数为3枚(四分位距2-3),放射性同位素为2枚(四分位距2-3)(P<0.001)。
  • 靶向腋窝清扫中,超顺磁性氧化铁纳米颗粒检出率100%,放射性同位素81.8%(P=0.124);指标淋巴结磁性检出93.9%,放射性检出66.7%(P=0.007)。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Superparamagnetic iron nanoparticles perform comparably to radioisotope ± blue dye for sentinel lymph node detection in breast cancer, even when injected up to 8 weeks before surgery. Using superparamagnetic iron nanoparticles for sentinel lymph node detection after primary systemic therapy, and the maximum time frame of superparamagnetic iron nanoparticle administration have not been investigated. METHODS: This cohort study included cN0/1-to-ycN0 patients undergoing sentinel lymph node detection or targeted axillary dissection. All patients received superparamagnetic iron nanoparticles either before primary systemic therapy or before surgery, and radioisotope on the day of surgery. RESULTS: For 113 patients analysed, superparamagnetic iron nanoparticles were injected a median of 3 (range 0-248) days before surgery, with a 97.4% detection rate compared with 91.2% for radioisotope (P = 0.057). Concordance for radioisotope was 97.1% and this was not affected by timing of superparamagnetic iron nanoparticle injection (Kendall's tau 0.027; P = 0.746). The median sentinel lymph node yield was 3 (interquartile range (i.q.r.) 2-3) for superparamagnetic iron nanoparticles and 2 (i.q.r. 2-3) for radioisotope (P < 0.001). In targeted axillary dissection, detection was 100% for superparamagnetic iron nanoparticles and 81.8% for radioisotope (P = 0.124). The index node was magnetic in 93.9% and radioactive in 66.7% (P = 0.007), an outcome that was not affected by any factors. For patients with metastases, superparamagnetic iron nanoparticle detection was 100% and radioisotope-based detection was 84.2% (P = 0.083), with superparamagnetic iron nanoparticles detecting more metastatic sentinel lymph nodes (median of 1 (i.q.r. 1-2) for superparamagnetic iron nanoparticles compared with a median of 1 (i.q.r. 0-1) for radioisotope; P = 0.005). CONCLUSION: Injection before primary systemic therapy is feasible and does not affect concordance with radioisotope. Superparamagnetic iron nanoparticles perform comparably to radioisotope, but detect more sentinel lymph nodes and have a higher rate of detection of metastatic sentinel lymph nodes.

来源:Br J Surg,查看原文。版权归原作者所有。

引用

  1. Pantiora E, Eriksson S, Wärnberg F, et al. Magnetically guided surgery after primary systemic therapy for breast cancer: implications for enhanced axillary mapping. Br J Surg. 2024. PMID: 38325801. doi:10.1093/bjs/znae008

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。